{
    "name": "tetrastarch",
    "comment": "Rx",
    "other_names": [
        "Voluven"
    ],
    "classes": [
        "Volume Expanders"
    ],
    "source": "https://reference.medscape.com/drug/voluven-tetrastarch-999927",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: Unknown if distributed in human breast milk"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Unknown if distributed in human breast milk"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Do not use hydroxyethyl starch (HES) in critically ill adults (including sepsis)",
                "Use of HES increases risk of mortality and renal replacement therapy in critically ill adults"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Critically ill adults, including those with sepsis (see Black Box Warnings)",
                "Severe liver disease",
                "Hypersensitivity",
                "Clinical conditions with volume overload",
                "Pre-existing coagulation or bleeding disorders",
                "Renal failure with oliguria or anuria not related to hypovolemia",
                "Patients receiving dialysis treatment",
                "Severe hypernatremia or hyperchloremia",
                "Intracranial bleeding"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Anaphylactoid reactions (mild influenza-like symptoms, bradycardia, tachycardia, bronchospasm, noncardiac pulmonary edema) reported",
                "Avoid use with pre-existing renal dysfunction; discontinue at the first sign of renal injury",
                "Monitor renal function for at least 90 days following administration",
                "Monitor coagulation status of patients undergoing open heart surgery in association with cardiopulmonary bypass as excess bleeding has been reported with HES solutions in this population; discontinue at the first sign of coagulopathy",
                "Avoid fluid overload; adjust dosage with cardiac or renal dysfunction",
                "In cases of severe dehydration, a crystalloid solution should be given first",
                "Monitor fluid balance, serum electrolytes, renal and hepatic function, acid-base balance, and coagulation parameters during prolonged parenteral therapy or when warranted"
            ],
            "specific": [
                {
                    "type": "Interference with laboratory tests",
                    "description": [
                        "Elevated serum amylase levels may be observed and can interfere with the diagnosis of pancreatitis",
                        "High doses may result in dilutional effects (eg, decreased levels of coagulation factors and other plasma proteins, decreased hematocrit)"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Pruritus",
            "percent": null
        },
        {
            "name": "Increased serum amylase",
            "percent": null
        },
        {
            "name": "Decreased coagulation factors",
            "percent": null
        },
        {
            "name": "Decreased hematocrit",
            "percent": null
        },
        {
            "name": "Anaphylactoid reactions",
            "percent": null
        }
    ]
}